Pheton Acquires 51% of iTonic, Expanding into Home Health Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Globenewswire
- Strategic Acquisition: Pheton successfully acquires 51% of iTonic, marking its expansion into the U.S. home health market, which is expected to enhance the company's competitiveness in the healthcare technology sector.
- Equity Structure Adjustment: The transaction involves issuing 4 million new Class A shares to selling shareholders, along with warrants for 3 million shares, aimed at incentivizing shareholders through performance milestones and strengthening corporate governance.
- Market Potential: iTonic addresses 125,000 preventable deaths and $500 billion in annual U.S. health costs linked to medication non-adherence, and Pheton's acquisition will facilitate more efficient home health solutions.
- Future Outlook: Pheton's CEO states that this acquisition will drive the company's transition to AI-driven health solutions, expected to create long-term value for shareholders and further solidify its position in the healthcare industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTHL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTHL
About PTHL
iTonic Holdings Ltd, formerly Pheton Holdings Ltd, is a holding company principally engaged in the provision of healthcare solutions through its subsidiary Beijing Feitian Zhaoye Technology Co., Ltd. (Beijing Feitian). The Company’s main businesses include development and commercialization of brachytherapy treatment planning system (TPS) specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. TPS is generally a computer software used in different types of radiotherapy. The Company’s main product is FTTPS, a user-oriented TPS for treating a wide variety of malignant tumors. Beijing Feitian’s product portfolio also includes Medical Auxiliary Supplies such as seed implant needles, computer workstations, patient positioning device and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pheton Acquires 51% of iTonic, Expanding into Home Health Market
- Strategic Acquisition: Pheton successfully acquires 51% of iTonic, marking its expansion into the U.S. home health market, which is expected to enhance the company's competitiveness in the healthcare technology sector.
- Equity Structure Adjustment: The transaction involves issuing 4 million new Class A shares to selling shareholders, along with warrants for 3 million shares, aimed at incentivizing shareholders through performance milestones and strengthening corporate governance.
- Market Potential: iTonic addresses 125,000 preventable deaths and $500 billion in annual U.S. health costs linked to medication non-adherence, and Pheton's acquisition will facilitate more efficient home health solutions.
- Future Outlook: Pheton's CEO states that this acquisition will drive the company's transition to AI-driven health solutions, expected to create long-term value for shareholders and further solidify its position in the healthcare industry.
Continue Reading
Pheton Acquires 51% of iTonic, Expanding into Home Health Market
- Strategic Acquisition: Pheton's successful acquisition of 51% of iTonic marks its expansion into the U.S. home health market, which is expected to enhance the company's competitiveness in the healthcare technology sector.
- Equity Structure: The transaction involves issuing 4 million new Class A shares and 3 million warrants to the Selling Shareholders, aimed at incentivizing long-term growth through performance milestones.
- Market Potential: iTonic addresses 125,000 preventable deaths and $500 billion in annual U.S. health costs linked to medication non-adherence, highlighting its significant market potential in home health.
- Future Outlook: Pheton's CEO stated that the acquisition will integrate iTonic's AI-driven platform to improve service quality for patients and caregivers, with expectations of significant value creation for shareholders.
Continue Reading